(Q35030557)

5 August 2017

1 reference

title

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians (English)

1 reference

5 August 2017

0 references

William Jeffery Sandborn

series ordinal

1

object named as

William J Sandborn

1 reference

5 August 2017

2

Stephen B Hanauer

1 reference

PubMed ID

12492177

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

The American Journal of Gastroenterology

5 August 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

5 August 2017

97

1 reference

5 August 2017

2962-2972

1 reference

5 August 2017

12

1 reference

Management of Crohn's disease in adults

5 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Use of infliximab in the treatment of Crohn's disease in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Use of infliximab in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab for the treatment of orofacial Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Does administration of infliximab increase susceptibility to listeriosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab in Crohn's disease: first anniversary clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Rapid response of severe refractory metastatic Crohn's disease to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Successful treatment of refractory esophageal Crohn's disease with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Infliximab for refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Severe anaphylactic reaction to infliximab: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Reactivation of histoplasmosis after treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

Listeria meningitis after treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.07093.X

10.1111/J.1572-0241.2002.07093.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12492177